All In Biotech

Drug Trial Radar · NCT04677439

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Efficacy and the Safety of Flumatinib in Treatment of CML-CP Patients With Ph+ Post Imatinib Failure

Last checked: Nov 19, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 1, 2021

Primary completion

May 30, 2023

Study completion Dec 30, 2023

Sponsor

Lead sponsor
Shenzhen Second People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hainan General Hospital; Sanya Central Hospital; First Affiliated Hospital of Shantou University Medical College; Peking University Shenzhen Hospital; Dongguan People's Hospital
First posted
Dec 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.

Conditions

  • Flumatinib
  • Chronic Myeloid Leukemia, Chronic Phase
  • Imatinib

Interventions

  • FlumatinibDrug

    600 mg of Flumatinib orally daily for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test.Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second People's Hospital of Shenzhen

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.